Protective effect of telmisartan on rats with renal failure and its mechanism

Abstract

A B S T R A C TObjective: To study the protective effect of telmisartan on rats with renal failure and its mechanism. Methods: 60 Wistar rats were chosen as study objective, and were divided into 4 groups randomly: 15 in group A (sham operation group), 15 in group B (model group), 15 in group C (telmisartan group) and 15 in group D (telmisartan + GW9962 group). The difference of survival rate, blood-urine biochemical indexes, renal pathological change, and the expression level of PPARg and nNOS were compared. Results: After 12 weeks, the survival rate of group A was 93.33% (14/15), that of group B was 46.67% (7/15), that of group C was 86.67% (13/15), that of group D was 60.00% (9/15), and the difference among 4 groups had statistical significance (P < 0.05). After 1 week, the difference of Scr, that of BUN and that of 24 h protein urine among 4 groups was not statistical significant (P > 0.05); after 3 weeks, 6 weeks and 12 weeks, these difference was statistical significant (P < 0.05). The difference of blood-urine biochemical indexes, that of renal pathological change, and that of the expression level of PPARg and nNOS was statistical significant (P < 0.05). Conclusions: Telmisartan has protective effect on renal failure caused by 5/6 nephrectomy, which might be relative to the expression level of PPARg and nNOS.

Telmisartan alleviates collagen type&nbsp;III glomerulopathy: A case report with literature review

“…Furthermore, telmisartan is able to attenuate renal podocyte apoptosis and autophagy-associated protein expression levels (7). Finally, telmisartan may have anti-fibrotic effects in human mesangial cells and reportedly decreased the expression levels of PPARγ and nNOS to delay the progression of renal failure (8)(9)(10)(11). Long term follow-up of the present case included the thorough and persistent monitoring for disease progression, which may be recommended for telmisartan as a first-line treatment for CG.…”

“…Medicinal approaches include inhibitors of angiotensin-converting enzyme (ACE) and of angiotensin II receptor blockers (ARB) (25). There are certain common adverse effects of ACE inhibitors, including coughing, renal dysfunction and hyperkalemia, and, in particular, prominent angioedema (11). ARB drugs are effective in reducing the risk of end-stage renal disease in patients with diabetic nephritis and decreased serum creatinine levels two-fold compared to those obtained with ACE inhibitors (25).…”

“…Treatment with angiotensin II receptor blockers, including telmisartan, may decrease the glomerular pressure and a previous report indicated that telmisartan is able to attenuate kidney cell apoptosis and autophagy-associated protein expression in kidney diseases (7). Furthermore, telmisartan has anti-fibrotic effects in human mesangial cells and decreased the expression levels of the peroxisome transcription factor peroxisome proliferator-activated receptor (PPAR)γ and the L-arginine-dependent neuronal nitric oxide synthase (nNOS) to delay the progression of renal failure (8)(9)(10)(11). To the best of our knowledge, the present study was the first to report a case of nephrotic syndrome (NS) with CG in northeastern China.…”

Protective effects of ethanolic extract of Alhagi maurorum roots on renal failure induced by acetaminophen in mice

“…6,7 Renal failure is complete or partial damage of kidney functions that may be chronic and acute. 8 The life of patients with renal failure depends on dialysis or kidney transplant which are costly. Li et al, 9 reported that ethanolextract of Chinese chive water in a concentration of 200 mg/kg/day given to adenine-induced chronic renal failure (CRF) mice model led to significant decrease of renal pathological damage to 48.1%, and decrease values of serum creatinine and blood urea nitrogen to 87.7% and 83.9%, respectively.…”